Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration to advance drug development for those affected by epidermolysis bullosa (EB). EB is a group of rare, genetic skin disorders with no known cure, meaning new treatments are a highly pressing medical need. The partners will initially focus on improving […]
The post DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder appeared first on Pharmafile.
